Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients

Contributed by: PR Newswire

Tags

CurasightAnnouncement

More Like This

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

Curatis on track: submission of orphan drug designation application in the US for lead product candidate

Business Wire logo

Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

Business Wire logo

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3

Oxford Set To Benefit From New Technology to Diagnose Disease

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us